Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL

NCT01851551 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin's Lymphoma
Diffuse Large B-cell Lymphoma
Mantle Cell Lymphoma

Interventions

DRUG: Vincristine Sulfate Liposome Injection plus rituximab

Sponsor

Acrotech Biopharma Inc.